http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
동종 골수이식을 시행받은 환자에서 폐색성 세기관지염에 의하여 발생한 자발성 기종격동과 피하 기종
이병환,이제중,이연경,안재숙,김여경,황호인,박무림,조상희,정익주,김형준 대한조혈모세포이식학회 2002 대한조혈모세포이식학회지 Vol.7 No.2
저자들은 만성골수성백혈병으로 동종 골수이식과 이식편 부전으로 인하여 추가적인 말초혈액 조혈모세포이식을 시행 받은 환자에서 만성 이식편대숙주질환과 그 폐 합병증인 폐색성 세기관지염에 동반된 자발성 기종격동과 피하 기종이 병발한 1예를 경험하였기에 이를 보고하는 바이다. Obstructive lung disorders following after allogeneic bone marrow transplantation (BMT) in association with graft- versus-host disease (GVHD) contribute significant morbidity and mortality. We report a case of a 28-year-old man who developed spontaneous pneumomediatinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic BMT. He received an allogeneic BMT for chronic phase of chronic myeloid leukemia. Five months after BMT, he was boostered by allogeneic peripheral blood stem cells from the same donor due to graft failure. One month after the boostering, chronic GVHD developed and were treated with cyclosporine and steroid. The patients developed spontaneous pneumomediatinum and subcutaneous emphysema secondary to severe bronchiolitis obliterans 4 months after boostering donor cells. The air-leak syndromes were recovered by conservative management, including high-flow oxygen.
말초혈액으로부터 Clini-MACS®를 이용한 CD34 양성세포 분리의 안정성과 효율성
박성규,이남수,원종호,박희숙,김원석,박찬형,김현수,김효철,김형준,홍영선,김춘추,홍대식 대한조혈모세포이식학회 2002 대한조혈모세포이식학회지 Vol.7 No.1
연구배경: 최근 자가 또는 동종조혈모세포이식 분야에서 말초혈액에서 채취된 단핵구 중 CD34 양성 세포만을 선택적으로 분리하여 조혈모세포이식에 응용되고 있는데 일부 악성 림프종, 유방암, 다발성 골수종 환자에서 종양세포의 오염 가능성을 감소시키고 자가면역질환이나 동종 조혈모세포이식 중 병적으로 활성화된 T 림프구를 제거할 목적으로 사용되어 치료성적 향상에 도움이 될 것으로 기대된다. 방법: 저자들은 고용량항암요법의 적응이 되는 예후가 불량한 악성 림프종(n=14), 유방암(n=5), 다발성 골수종(n=1)을 앓고 있는 20명의 환자들을 대상으로 말초혈액으로부터 Clini-MACS®을 사용하여 선택적으로 분리한 CD34 양성세포만을 이용한 조혈모세포이식의 안정성과 효율성을 분석하고자 하였다. 분리방법의 효율성을 확인하기 위하여 CD34 양성세포 분리 전후에 단핵구 수, CD34 양성률 및 세포수를 분석하고 CD34 양성세포의 순도 및 획득률을 계산하였으며 CFU-GM 집락 배양검사와 같은 질적 분석도 병행하였다. 실제 이식이 진행된 경우는 15명이었으며 조혈모세포이식 이후 골수기능의 회복 정도를 분석하여 안정성을 확인하였다. 결과: 분리 전의 CD34 양성세포 수는 1.30×10^(8) (range 0.30~29.0)이었으며 분리 후의 CD34 양성세포 수는 0.93×10^(8) (range 0.11~10.80)이었고 CD34 양성세포의 순도는 96.0% (range 35.7~99.9%)이었으며 획득률은 70.5% (range 34.5~94.4%)이었다. 말초혈액 조혈모세포가 채취되었던 20명 중 15명이 고용량항암요법 후 조혈모세포이식이 이루어졌으며 CD34 양성세포의 수는 2.12×10^(6)/kg (range 0.44~18.1)이었다. 조혈모세포이식 후 골수기능 회복에 대한 분석에서 호중구 500/μL 이상으로 회복된 시기는 이식 후 12일째 (range 7~36일)이었고 혈소판 수가 20,000/μL 이상 유지된 시기는 15일째 (10~43일)이었다. 2명의 환자에서 3주 내에 골수정착이 이루어지지 않아 추가적인 조혈모세포 투입이 이루어졌고 그 이후 성공적인 정착이 이루어졌으며 특히, 2.0×10^(6)/kg 이상의 CD34 양성세포를 확보한 경우에서 보다 빠른 백혈구 및 혈소판 회복을 보였다(ANC>500/μL; 9 days vs 13 days, platelet>20,000/μL; 8 days vs 16 days). 320일간 추적관찰을 통하여 9명이 생존 중이며 이중 1명이 재발하여 동종조혈모세포이식을 시행하였으며 사망한 6명 교통사고로 사망한 1명 제외한 5명은 재발 후 병의 진행으로 사망하였다. 전체 생존율은 56.9%이었으며 무병생존율은 50.9%이었고 중앙 생존기간은 아직 도달하지 않았다. 결론: 말초혈액 CD34 양성세포을 이용한 조혈모세포이식은 안정적으로 이루어질 수 있으며 특히 조기 골수기능회복을 위해서는 2.0×10^(6)/kg 이상의 CD34 양성세포를 확보하여야 할 것으로 생각된다. 또한, Clini-MACS®을 이용한 CD34 양성세포의 선택적 분리는 효과적으로 이루어졌으나 향후 광범위한 연구가 필요할 것으로 생각된다. Background: The leukapheresis products of patients with breast cancer, multiple myeloma, and low grade lymphoma contain significant numbers of malignant cells. Results of previous studies suggested that graft-contaminating tumor cells can have an impact on clinical outcome. Recently, a number of devices have been developed for the positive selection of CD34+ peripheral blood progenitor cells for clinical use in autologous or allogeneic transplantation. The rationale for CD34+ selection is based on clinical studies showing a two to five log reduction of contaminating tumor cells in patients with breast cancer, multiple myeloma and low grade lymphoma. Methods: We have investigated the safety and efficacy of the CD34+ selection of peripheral blood progenitor cells for auto-transplantation. Twenty patients (14 malignant lymphomas, 5 breast cancers, 1 multiple myeloma) were mobilized using chemotherapy plus G- or GM-CSF. Results: The leukapheresis products from twenty patients with a median of 1.30×10 exp (8) (range 0.30~29.0) CD34+ cells were collected during mobilization. After Clini-MACS® procedure, the median number of CD34+ selected cells was 0.93×10 exp (8) (range 0.11~10.80) with a median recovery of 70.5% (range 34.5~94.4%) and a median purity of 96.0% (range 35.7~99.9%). Fifteen patients have been infused with CD34+ selected grafts after myeloablative preparation. The median number of reinfused CD34+ cells was 2.12×10 exp (6)/kg (range 0.44~18.1). The median time to reach an absolute neutrophil count of 500/μL and an unsupported platelet count of 20,000/μL were 12 days (range 7~36) and 15 days (range 10~43), respectively. But two patients were not reconstituted bone marrow function until 3 weeks after CD34+ cell infusion. They received un-manipulated PBPC in addition to selected CD34+ cells and then all had successive engraftment. Patients who received more than 2.0×10 exp (6) CD34+ cells/kg showed a significantly faster neutrophil and platelet recovery than patients who received less than 2.0×10 exp (6) CD34+ cells/kg (log-rank test, p<0.05). With a median follow-up of 320 days, 9 patients are alive without disease recurrence and 5 patients died of relapse. Conclusion: The selection of CD34+ cells using Clini-MACS® yield highly purified autografts, and also the engraftment ability of the progenitor and stem cells is fully retained. And auto-transplantation of CD34+ PBPC results in a rapid and stable neutrophil and platelet engraftment in patients who received an infused dose of at least 2.0×10 exp (6) CD34+ cells/kg. Further additional randomized phase III trials are required to determine whether tumor cell purging by CD34+ cell selection will have a significant impact on progression-free and overall survival in autologous transplantation.
용융탄산염 연료전지용 Ni, NiO (Li) cathode 의 소결특성 및 용해거동
박형호,이규택 대한금속재료학회(대한금속학회) 1996 대한금속·재료학회지 Vol.34 No.4
In-situ Ni and ex-situ NiO(Li) cathodes were fabricated by cold pressing using Ni powder and Li₂CO₃(in case of ex-situ cathode) with paraffin wax as a binder. The characteristics of in-situ and ex-situ cathodes according to the sintering temperature were examined. Also the behavior of the in-situ and ex-situ cathodes under the MCFC operation condition were investigated in this study. The optimum sintering temperature was 800℃ of neck growth step leading to the porosity of about 70% and strength of about 350MPa. To obtain reasonably high electric conductivity in ex-situ cathode, the sintering temperature was chosen to be below 950℃ to maintain the cation fraction of L^+ in the range of 0.02∼0.06. In terms of the Ni-dissolution rate, ex-situ cathode was more efficient than in-situ cathode in the long-term operation except the initial 24hr. Corrosion product was Li₂NiO_(10) at the in-situ and ex-situ cathodes.
Bai, Yu,Park, Il Song,Park, Hyeoung Ho,Lee, Min Ho,Bae, Tae Sung,Duncan, Warwick,Swain, Michael John Wiley Sons, Ltd. 2011 Surface and interface analysis Vol.43 No.6
<P><B>Abstract</B></P><P>Well‐ordered TiO<SUB>2</SUB> nanotubes were prepared by the electrochemical anodization of titanium in an ethylene glycol electrolyte containing 1 wt% NH<SUB>4</SUB>F and 10 wt% H<SUB>2</SUB>O at 20 V for 20 min, followed by annealing. The surface morphology and crystal structure of the samples were examined as a function of the annealing temperature by field emission scanning electron microscopy (FE‐SEM) and X‐ray diffraction (XRD), respectively. Crystallization of the nanotubes to the anatase phase occurred at 450 °C, while rutile formation was observed at 600 °C. Disintegration of the nanotubes was observed at 600 °C and the structure vanished completely at 750 °C. Electrochemical corrosion studies showed that the annealed nanotubes exhibited higher corrosion resistance than the as‐formed nanotubes. The growth of hydroxyapatite on the different TiO<SUB>2</SUB> nanotubes was also investigated by soaking them in simulated body fluid (SBF). The results indicated that the tubes annealed to a mixture of anatase and rutile was clearly more efficient than that in their amorphous or plain anatase state. The <I>in vitro</I> cell response in terms of cell morphology and proliferation was evaluated using osteoblast cells. The highest cell activity was observed on the TiO<SUB>2</SUB> nanotubes annealed at 600 °C. Copyright © 2010 John Wiley & Sons, Ltd.</P>